A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer

10.1186/s12885-018-4234-8

Saved in:
Bibliographic Details
Main Authors: Sundar, R, Rha, S.Y, Yamaue, H, Katsuda, M, Kono, K, Kim, H.S, Kim, C, Mimura, K, Kua, L.-F, Yong, W.P
Other Authors: LIFE SCIENCES INSTITUTE
Format: Article
Published: 2020
Subjects:
Online Access:https://scholarbank.nus.edu.sg/handle/10635/175397
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: National University of Singapore
id sg-nus-scholar.10635-175397
record_format dspace
spelling sg-nus-scholar.10635-1753972024-04-25T02:38:39Z A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer Sundar, R Rha, S.Y Yamaue, H Katsuda, M Kono, K Kim, H.S Kim, C Mimura, K Kua, L.-F Yong, W.P LIFE SCIENCES INSTITUTE SURGERY DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) CANCER SCIENCE INSTITUTE OF SINGAPORE alkaline phosphatase aspartate aminotransferase cancer vaccine HLA A antigen otgsc a24 otsgc a24 peptide vaccine unclassified drug biological marker cancer vaccine HLA A24 antigen subunit vaccine abdominal pain adult advanced cancer adverse outcome aged alkaline phosphatase blood level anemia antineoplastic activity Article aspartate aminotransferase blood level cancer pain clinical article cohort analysis constipation controlled study coughing cytotoxic T lymphocyte decreased appetite diarrhea dizziness drug effect drug efficacy drug response drug safety drug tolerability dyspepsia dysphagia dyspnea enzyme linked immunospot assay ex vivo study female fever gastrointestinal reflux haplotype human hyperbilirubinemia hyperkalemia hypokalemia hyponatremia immune response injection site erythema injection site ulcer loss of appetite lung infection malaise male myalgia nausea open study overall survival peripheral edema phase 1 clinical trial progression free survival pruritus stomach cancer stomach tumor survival rate treatment outcome upper respiratory tract infection vaccination vomiting cancer staging clinical trial cytotoxicity genetics immunology metabolism metastasis middle aged mortality multimodality cancer therapy pathology stomach tumor Adult Aged Biomarkers Cancer Vaccines Combined Modality Therapy Cytotoxicity, Immunologic Female Haplotypes HLA-A24 Antigen Humans Male Middle Aged Neoplasm Metastasis Neoplasm Staging Stomach Neoplasms T-Lymphocytes, Cytotoxic Vaccines, Subunit 10.1186/s12885-018-4234-8 BMC Cancer 18 1 332 2020-09-09T10:30:08Z 2020-09-09T10:30:08Z 2018 Article Sundar, R, Rha, S.Y, Yamaue, H, Katsuda, M, Kono, K, Kim, H.S, Kim, C, Mimura, K, Kua, L.-F, Yong, W.P (2018). A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 18 (1) : 332. ScholarBank@NUS Repository. https://doi.org/10.1186/s12885-018-4234-8 1471-2407 https://scholarbank.nus.edu.sg/handle/10635/175397 Unpaywall 20200831
institution National University of Singapore
building NUS Library
continent Asia
country Singapore
Singapore
content_provider NUS Library
collection ScholarBank@NUS
topic alkaline phosphatase
aspartate aminotransferase
cancer vaccine
HLA A antigen
otgsc a24
otsgc a24
peptide vaccine
unclassified drug
biological marker
cancer vaccine
HLA A24 antigen
subunit vaccine
abdominal pain
adult
advanced cancer
adverse outcome
aged
alkaline phosphatase blood level
anemia
antineoplastic activity
Article
aspartate aminotransferase blood level
cancer pain
clinical article
cohort analysis
constipation
controlled study
coughing
cytotoxic T lymphocyte
decreased appetite
diarrhea
dizziness
drug effect
drug efficacy
drug response
drug safety
drug tolerability
dyspepsia
dysphagia
dyspnea
enzyme linked immunospot assay
ex vivo study
female
fever
gastrointestinal reflux
haplotype
human
hyperbilirubinemia
hyperkalemia
hypokalemia
hyponatremia
immune response
injection site erythema
injection site ulcer
loss of appetite
lung infection
malaise
male
myalgia
nausea
open study
overall survival
peripheral edema
phase 1 clinical trial
progression free survival
pruritus
stomach cancer
stomach tumor
survival rate
treatment outcome
upper respiratory tract infection
vaccination
vomiting
cancer staging
clinical trial
cytotoxicity
genetics
immunology
metabolism
metastasis
middle aged
mortality
multimodality cancer therapy
pathology
stomach tumor
Adult
Aged
Biomarkers
Cancer Vaccines
Combined Modality Therapy
Cytotoxicity, Immunologic
Female
Haplotypes
HLA-A24 Antigen
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Stomach Neoplasms
T-Lymphocytes, Cytotoxic
Vaccines, Subunit
spellingShingle alkaline phosphatase
aspartate aminotransferase
cancer vaccine
HLA A antigen
otgsc a24
otsgc a24
peptide vaccine
unclassified drug
biological marker
cancer vaccine
HLA A24 antigen
subunit vaccine
abdominal pain
adult
advanced cancer
adverse outcome
aged
alkaline phosphatase blood level
anemia
antineoplastic activity
Article
aspartate aminotransferase blood level
cancer pain
clinical article
cohort analysis
constipation
controlled study
coughing
cytotoxic T lymphocyte
decreased appetite
diarrhea
dizziness
drug effect
drug efficacy
drug response
drug safety
drug tolerability
dyspepsia
dysphagia
dyspnea
enzyme linked immunospot assay
ex vivo study
female
fever
gastrointestinal reflux
haplotype
human
hyperbilirubinemia
hyperkalemia
hypokalemia
hyponatremia
immune response
injection site erythema
injection site ulcer
loss of appetite
lung infection
malaise
male
myalgia
nausea
open study
overall survival
peripheral edema
phase 1 clinical trial
progression free survival
pruritus
stomach cancer
stomach tumor
survival rate
treatment outcome
upper respiratory tract infection
vaccination
vomiting
cancer staging
clinical trial
cytotoxicity
genetics
immunology
metabolism
metastasis
middle aged
mortality
multimodality cancer therapy
pathology
stomach tumor
Adult
Aged
Biomarkers
Cancer Vaccines
Combined Modality Therapy
Cytotoxicity, Immunologic
Female
Haplotypes
HLA-A24 Antigen
Humans
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Stomach Neoplasms
T-Lymphocytes, Cytotoxic
Vaccines, Subunit
Sundar, R
Rha, S.Y
Yamaue, H
Katsuda, M
Kono, K
Kim, H.S
Kim, C
Mimura, K
Kua, L.-F
Yong, W.P
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
description 10.1186/s12885-018-4234-8
author2 LIFE SCIENCES INSTITUTE
author_facet LIFE SCIENCES INSTITUTE
Sundar, R
Rha, S.Y
Yamaue, H
Katsuda, M
Kono, K
Kim, H.S
Kim, C
Mimura, K
Kua, L.-F
Yong, W.P
format Article
author Sundar, R
Rha, S.Y
Yamaue, H
Katsuda, M
Kono, K
Kim, H.S
Kim, C
Mimura, K
Kua, L.-F
Yong, W.P
author_sort Sundar, R
title A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
title_short A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
title_full A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
title_fullStr A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
title_full_unstemmed A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
title_sort phase i/ib study of otsgc-a24 combined peptide vaccine in advanced gastric cancer
publishDate 2020
url https://scholarbank.nus.edu.sg/handle/10635/175397
_version_ 1800914361681707008